Neurona Therapeutics’ Post

Sudden Unexpected Death in Epilepsy (SUDEP) remains a critical concern in epilepsy management, with the underlying mechanisms still not fully understood. Our latest blog explores a recent study by Iyer, S., et al (2024) that investigates how altered ventilatory responses to hypercapnia-hypoxia (HH) challenges in a preclinical SUDEP model implicate orexin neurons: https://hubs.ly/Q02Gy87z0 #SUDEP #Orexins #Plethysmography #NeuralControlOfBreathing

2 minutes flash-talk, presenting the results of our work on PSWEs, a promising biomarker of epilepsy, at the 35th congress of the ILAE. #ILAE #IEC #35thcongress #epilepsy

Breaking new ground in nerve injury and repair models! MD Biosciences offers preclinical rodent and porcine models for cutting-edge neuropathic pain research, pushing the boundaries of our understanding of pain mechanisms and testing therapeutic applications. Explore our models for peripheral nerve injury and repair, including our translational pig model for peripheral trauma. Read more about the different nerve injury and repair models: https://hubs.la/Q02mrc8x0 #neuropathicpain #painresearch #drugdevelopment #translationalmodels

RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPγ8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy. Whereas AMPARs are distributed widely in the CNS, TARPγ8 is expressed only in discrete regions – most enriched in the hippocampus (which is often involved in focal epilepsies) and also present in the amygdala and cortex. Because of this restricted expression of #TARPγ8, we believe #RAP-219 has the potential to provide a differentiated clinical profile, including improved activity and tolerability along with a higher #therapeutic index, potentially providing more patients with #sustained therapeutic benefit without intolerable side effects. #CNS #Innovativebiotech #Innovation #Drugdevelopment #Newmodalities #Epilepsy #IPO #Patientcentricity

Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease..... Papp, K.V., et al. https://lnkd.in/e4AMKteK #Alzheimerscognitive #Amyloid #Neuropsychological

Today, we honor a landmark in medical science: the development of phenobarbital, the first effective treatment for epilepsy. 🧠 Since its introduction in 1912, this drug would remain one of only a handful of treatments for those with epilepsy until the 1970s. Today, there are more than 25 drugs available for treatment, opening doors to a life less constrained by the condition, but more are needed to improve quality of life for all with epilepsy disorders. As a preclinical CRO, we are inspired by this historical breakthrough and are committed to advancing epilepsy therapies further. The journey of discovery continues, and with our pioneering technologies and expert research scientists, the future is bright. #MilestoneInMedicine #EpilepsyAwareness #epilepsytreatments #CNSDiseases #Phenobarbital #InnovationInPharma #drugdiscovery

Morten Grunnet, Prof, PhD, DrSci, Vice President and Head of Neuroscience from Lundbeck is discussing: "Drug Discovery in CNS - An insights into Lundbeck's strategy of developing drugs to target the central nervous system Stay tuned for more! hashtag #Day1 hashtag #DDSS2023! hashtag #13thddss2023 hashtag #PharmaInnovation hashtag #UnlockPotential hashtag #summit2023 hashtag #staytunedformore Activate to view larger image,

Market Information - 16/01/2024 Exciting news in the healthcare industry! Genevant has secured a $114M deal with Tome to develop liver therapy. Meanwhile, Allakos has dropped their lead asset after mid-phase flops, leading to a halving of their headcount. In other news, Alto Neurosciences is preparing to go public with their CNS therapies. Additionally, the FDA has cleared an AI that predicts Alzheimer's progression from an MRI. Unfortunately, Novartis has backed out of their deal with Cytokinetics. Stay informed with the latest updates in the healthcare industry. #HealthcareNews #Genevant #Tome #Allakos #AltoNeurosciences #Cytokinetics #FDA #Alzheimers #MRI #HealthcareIndustry

Precision medicine has the potential to change the landscape of rare disease treatment by creating tailored medications that cater to the specific requirements of individual patients. However, this notion also brings forth unique regulatory obstacles that can stifle the research process and delay product commercialization. What factors make rare neurological disease a target for precision medicine, and how can we overcome key obstacles for these conditions? To learn more, read here: https://lnkd.in/eR3GTVbi #Allucent #BringNewTherapiesToLight #PrecisionMedicine #RareDisease #Neurology

Learn the key considerations for utilizing #RANO 2.0 criteria when assessing #Glioblastoma treatments in #ClinicalTrials. Read the blog by Calyx's Elif Sikoglu https://lnkd.in/gcztcF3m #MedicalImaging #NeuroOncology #ChooseCalyx